Indian stocks: Visit www.stage2stocks.com →

enGene Therapeutics Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, enGene Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $1.58, 87.0% below its 52-week high and below its 200-day average, which is falling.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. More about the company

$1.58
-3.07% today
$106M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ENGN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 15w
S4 17w
S4 31w
S2 24w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 3w → S4 8w → S1 3w → S2 10w → S3 6w → S4 17w → S1 9w → S4 31w → S1 7w → S2 24w → S3 7w → S4 14w → S1 9w → S4 1w current
Total tracked: 165 weeks across 15 stage runs.

ENGN among Biotechnology488th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…488ENGNStage 4 · wk 110−21.0%
vs 52W High
-87.0%
$1.44 lo$12.17 hi
87.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 1
1w13w26w
Week 1, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-65.5%
200 DMA: $4.58 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.71x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.0%
3M
-13.2%
6M
-80.6%
YTD
-82.1%
1Y
-81.4%
Scan Membership
Breakout Watch
Latest: 2024-03-11
2 appearances in last 60 days. First seen: 2022-11-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 1 · Vol 0.71x
2026-10-21S41→4
Wk 1 · Vol 1.28x
2026-10-20S1
Wk 10 · Vol 1.43x
2026-10-19S1
Wk 9 · Vol 1.01x
2026-10-16S1
Wk 9 · Vol 1.53x
2026-10-15S1
Wk 9 · Vol 1.60x
2026-10-14S1
Wk 9 · Vol 1.29x
2026-10-13S1
Wk 9 · Vol 1.27x
2026-10-12S1
Wk 8 · Vol 0.64x
2026-10-09S1
Wk 8 · Vol 0.49x
2026-10-08S1
Wk 8 · Vol 2.06x
2026-10-07S1
Wk 8 · Vol 1.00x
Moving averages & range
50 DMA
$1.82
200 DMA
$4.58
52W High
$12.17
52W Low
$1.44
5D Low
$1.58
Resistance levels (recent highs)
20d High
$2.00
60d High
$2.05
120d High
$8.85
250d High
$12.17
Next resistance
+26.6%
to 20d High
ROE
-60.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.5

enGene Therapeutics: quick answers

What stage is enGene Therapeutics in?

As of Oct 22, 2026, enGene Therapeutics (ENGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is enGene Therapeutics in an uptrend?

No. enGene Therapeutics is in a Stage 4 downtrend. It trades 65.5% below its 200-day average, which is falling.

How far is enGene Therapeutics from its 52-week high?

enGene Therapeutics closed at $1.58 on Oct 22, 2026, 87.0% below its 52-week high of $12.17. Its 52-week low is $1.44.

How has enGene Therapeutics performed over the past year?

As of Oct 22, 2026, enGene Therapeutics is down 81.4% over the past year and down 82.1% so far in 2026.

Which sector and industry is enGene Therapeutics in?

enGene Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.